Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human B7-H2 / ICOSLG Protein, 2 x500 µg  

Recombinant Human B7-H2 / ICOSLG Protein, 2 x500 µg

Human B7-H2 / ICOSLG Protein (Human B7-H2, His Tag) Asp 19 - Ser 258 was produced in human 293 cells (HEK293), His Tag.

Synonym: recombinant human ICOSLG,B7-H2,B7H2,B7RP-1,ICOS ligand

More details

B72-H5221-1K

Availability: within 7 days

1 200,00 €

Background
ICOS ligand (ICOSLG) is also known as B7 homolog 2 (B7-H2), B7-related protein 1 (B7RP-1) and CD antigen CD275, which belongs to the immunoglobulin superfamily and BTN/MOG family. ICOSLG contains one Ig-like C2-type (immunoglobulin-like) domain and one Ig-like V-type (immunoglobulin-like) domain. Isoform 1 is widely expressed, while isoform 2 is detected only in lymph nodes, leukocytes and spleen. B7-H2 is ligand for the T-cell-specific cell surface receptor ICOS. B7-H2 acts as a costimulatory signal for T-cell proliferation and cytokine secretion and induces also B-cell proliferation and differentiation into plasma cells. B7-H2 could play an important role in mediating local tissue responses to inflammatory conditions, as well as in modulating the secondary immune response by co-stimulating memory T-cell function.

Source
Recombinant Human B7-H2, His Tag (B72-H5221) is expressed from human 293 cells (HEK293). It contains AA Asp 19 - Ser 258 (Accession # NP_056074).
Predicted N-terminus: Asp 19

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 27.8 kDa. The protein migrates as 45-67 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to  product data sheet.

Clinical and Translational Updates

(1) "Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer"
Yang, Tian, Gao et al
BMC Cancer (2022) 22 (1), 584
(2) "B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells"
Emaldi, Nunes-Xavier
Cells (2022) 11 (9)
(3) "CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia"
Kaito, Hirano, Futami et al
Oncol Lett (2022) 23 (2), 51
Showing 1-3 of 67 papers.